Pfizer (NYSE:PFE – Get Rating) has been given a $57.00 price objective by equities researchers at JPMorgan Chase & Co. in a note issued to investors on Tuesday, Borsen Zeitung reports. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 12.51% from the stock’s current price.
Several other research firms have also commented on PFE. Morgan Stanley began coverage on shares of Pfizer in a research note on Wednesday, April 6th. They set an “equal weight” rating and a $55.00 price objective for the company. The Goldman Sachs Group set a $51.00 price objective on shares of Pfizer in a research note on Wednesday, May 25th. Berenberg Bank set a $50.00 target price on shares of Pfizer in a report on Friday, May 27th. StockNews.com upgraded shares of Pfizer from a “buy” rating to a “strong-buy” rating in a report on Tuesday, April 19th. Finally, Wells Fargo & Company reduced their target price on shares of Pfizer from $60.00 to $55.00 in a report on Wednesday, May 4th. Nine research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and an average target price of $57.26.
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.
And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
PFE traded down $1.22 during trading hours on Tuesday, hitting $50.66. The company’s stock had a trading volume of 16,403,573 shares, compared to its average volume of 29,494,406. The business’s 50-day moving average price is $50.48 and its 200-day moving average price is $52.21. Pfizer has a 12 month low of $38.82 and a 12 month high of $61.71. The stock has a market cap of $284.25 billion, a price-to-earnings ratio of 11.62, a P/E/G ratio of 0.63 and a beta of 0.76. The company has a current ratio of 1.39, a quick ratio of 1.13 and a debt-to-equity ratio of 0.43.
Pfizer (NYSE:PFE – Get Rating) last posted its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 EPS for the quarter, missing the consensus estimate of $1.66 by ($0.04). The firm had revenue of $25.66 billion for the quarter, compared to analysts’ expectations of $24.73 billion. Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The firm’s quarterly revenue was up 76.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.93 earnings per share. On average, analysts forecast that Pfizer will post 6.61 earnings per share for the current year.
In other Pfizer news, EVP William R. Carapezzi, Jr. sold 32,908 shares of Pfizer stock in a transaction that occurred on Thursday, May 12th. The stock was sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the transaction, the executive vice president now owns 38,146 shares of the company’s stock, valued at $1,907,300. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Jennifer B. Damico sold 4,218 shares of Pfizer stock in a transaction on Tuesday, June 7th. The shares were sold at an average price of $53.96, for a total transaction of $227,603.28. Following the completion of the transaction, the senior vice president now owns 10,846 shares in the company, valued at $585,250.16. The disclosure for this sale can be found here. Insiders sold a total of 41,126 shares of company stock valued at $2,075,003 in the last quarter. Company insiders own 0.05% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. Bank OZK raised its position in Pfizer by 0.3% in the fourth quarter. Bank OZK now owns 68,883 shares of the biopharmaceutical company’s stock worth $4,067,000 after acquiring an additional 195 shares in the last quarter. TimeScale Financial Inc. raised its position in Pfizer by 2.9% in the fourth quarter. TimeScale Financial Inc. now owns 6,978 shares of the biopharmaceutical company’s stock worth $412,000 after acquiring an additional 196 shares in the last quarter. Fruth Investment Management grew its holdings in Pfizer by 0.7% in the fourth quarter. Fruth Investment Management now owns 29,313 shares of the biopharmaceutical company’s stock valued at $1,730,000 after purchasing an additional 200 shares during the last quarter. Winfield Associates Inc. grew its holdings in Pfizer by 0.9% in the fourth quarter. Winfield Associates Inc. now owns 21,557 shares of the biopharmaceutical company’s stock valued at $1,273,000 after purchasing an additional 200 shares during the last quarter. Finally, Birinyi Associates Inc. grew its holdings in Pfizer by 3.4% in the first quarter. Birinyi Associates Inc. now owns 6,000 shares of the biopharmaceutical company’s stock valued at $311,000 after purchasing an additional 200 shares during the last quarter. Institutional investors and hedge funds own 66.50% of the company’s stock.
About Pfizer (Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should you invest $1,000 in Pfizer right now?
Before you consider Pfizer, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Pfizer wasn’t on the list.
While Pfizer currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com